Spots Global Cancer Trial Database for XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

Official Title: A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC

Study ID: NCT01748851

Conditions

Gastric Carcinoma Stage IV

Interventions

XELOX

FOLFOX

Study Description

Brief Summary: The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced gastric cancer.

Detailed Description: Quality assurance: Data will be collected, controlled, and monitored at the Korean Clinical Study Group (KCSG) data center. Data will be entered throuGh the E-Case report form (CRF) (Web based data input) Korean Clinical Study Group (KCSG) data center will do the standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management Sample size assessment to specify the number of participants or participant years was consulted Statistical specialist. And data analysis will be also discuss with him Expected median progression-free survival(PFS) in Xelox: 6 months total number of events required: 359 197 patients will be needed After 10% of follow-up loss, 219 patients in each arm, a total of 438 patients will be enrolled